Bristol-Myers Squibb Co (BMYMP.PK)
--USD
--
-- (--)
$570.10
--
--
--
--
--
--
--
About
Overall
| Beta: | 0.39 |
| Market Cap (Mil.): | $71,187.03 |
| Shares Outstanding (Mil.): | 1,646.32 |
| Dividend: | 0.35 |
| Yield (%): | 3.24 |
Financials
| BMYMP.PK | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 37.93 | 37.76 |
| EPS (TTM): | -- | -- | -- |
| ROI: | -- | 19.48 | 18.76 |
| ROE: | -- | 20.17 | 19.59 |
CORRECTED-UPDATE 1-U.S. FDA puts hold on Vertex hepatitis study
(Corrects third paragraph to show hold on U.S. trial, not European study)
U.S. FDA puts hold on Vertex hepatitis study; shares fall
- Vertex Pharmaceuticals Inc said U.S. health regulators placed a partial clinical hold on its mid-stage study of an experimental oral hepatitis C treatment because of potential liver problems, sending its shares sharply lower on Thursday.
UPDATE 2-Bristol cuts forecast, new blood clot drug struggles
July 25 - U.S. drugmaker Bristol-Myers Squibb Co cut its full-year revenue and earnings forecasts and posted disappointing sales of its new drug to prevent blood clots and its once-weekly Bydureon diabetes drug.
Fitch Downgrades Bristol Myers Squibb's IDR to 'A-'; Outlook to Stable
(The following statement was released by the rating agency) CHICAGO, July 01 (Fitch) Fitch Ratings has downgraded Bristol-Myers Squibb Co.'s (Bristol Myers Squibb) long-term Issuer Default Rating (IDR) to 'A-' from 'A'. See a full list of affected ratings below. The ratings apply to approximately $7.3 billion of debt. The Rating Outlook is revised to Stable from Negative. KEY RATING DRIVERS --Operational pressure peaking in 2013: Plavix and Avapro patent expirations have negatively affect
Release of Eliquis blood clot preventer story
The blood clot preventer Eliquis, sold by Pfizer Inc and Bristol-Myers Squibb Co, proved as effective as widely used warfarin in treating a dangerous condition known as venous thromboembolism and caused far less bleeding, according to data from a large clinical trial.
UPDATE 2-Astra, Bristol diabetes drug disappoints in key test
LONDON, June 19 - AstraZeneca and Bristol-Myers Squibb's diabetes drug Onglyza failed to reduce heart risks in a large clinical study, disappointing investors who had thought it might demonstrate an edge over rivals.
AstraZeneca, Bristol diabetes drug disappoints in key test
LONDON - AstraZeneca and Bristol-Myers Squibb's diabetes drug Onglyza failed to reduce heart risks in a large clinical study, disappointing investors who had thought it might demonstrate an edge over rivals.
UPDATE 1-Former Bristol-Myers executive admits to insider trading
* Defendant accused of buying options in takeover targets
Former Bristol-Myers executive admits to insider trading
- A former Bristol-Myers Squibb Co finance executive on Monday pleaded guilty to an insider trading charge, admitting to buying stock options in a biotechnology company that the drugmaker was preparing to buy.
Former Bristol-Myers executive admits to insider trading
* Defendant accused of buying options in takeover targets
Competitors
| Price | Change | |
|---|---|---|
| Johnson & Johnson (JNJ.N) | $93.77 | +0.27 |
| Pfizer Inc. (PFE.N) | $29.11 | -0.12 |
| Merck & Co., Inc. (MRK.N) | $48.58 | +0.41 |
| Sanofi SA (SASY.PA) | €76.85 | -3.32 |
| AstraZeneca plc (AZN.L) | 3,334.00p | -1.00 |
| GlaxoSmithKline plc (GSK.L) | 1,712.50p | +28.50 |
| Eli Lilly & Co. (LLY.N) | $53.50 | +0.39 |

Estimates